Stocks of Iovance Biotherapeutics Inc (NASDAQ:IOVA) traded higher last session on Wall Street, up 1.16% to $1.75.
IOVA stock price is now -40.29% away from the 50-day moving average and -74.80% away from the 200-day moving average. The market capitalization of the company currently stands at $584.39M.
With the price target maintained at $2, UBS recently Downgraded its rating from Buy to Neutral for Iovance Biotherapeutics Inc (NASDAQ: IOVA)., while ‘Citizens JMP’ rates the stock as ‘Mkt Perform’
In other news, Puri Raj K., Chief Regulatory Officer bought 5,600 shares of the company’s stock on May 23 ’25. The stock was bought for $9,743 at an average price of $1.74. Upon completion of the transaction, the Chief Regulatory Officer now directly owns 206,852 shares in the company, valued at $0.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 14 ’25, Interim CEO & General Counsel Vogt Frederick G bought 25,000 shares of the business’s stock. A total of $42,250 was incurred on buying the stock at an average price of $1.69. This leaves the insider owning 374,646 shares of the company worth $0.66 million. A total of 18.67% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $1.64 and a high of $12.51. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 4.18, and a quick ratio of 3.64.
The net profit margin was -176.49% and return on equity was -51.85% for IOVA. The company reported revenue of $49.32 million for the quarter, compared to $0.71 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6798.46 percent. For the current quarter, analysts expect IOVA to generate $67.14M in revenue.
